NRX Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for NRX Pharmaceuticals (NRXP).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

5Buy

Consensus RatingBuy# Analysts5Avg. Consensus PT$30Upside to Avg. PT+1082.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 1, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$49→$50
Sep 14, 2026	BTIG	Thomas Shrader	Maintained	Buy	$10
Aug 25, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$45
Aug 18, 2026	BTIG	Thomas Shrader	Maintained	Buy	$10
Aug 7, 2026	BTIG	Thomas Shrader	PT Cut	Buy	$25→$10
May 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Apr 27, 2026	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$45
Apr 27, 2026	Ascendiant Capital	Edward Woo	PT Raise	Buy	$48→$49
Apr 23, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Apr 20, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 24, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 24, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Mar 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 16, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 9, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Mar 3, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$40→$45
Feb 18, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Feb 17, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34
Jan 15, 2026	BTIG	Thomas Shrader	Maintained	Buy	$25
Jan 5, 2026	D. Boral Capital	Jason Kolbert	Maintained	Buy	$34

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $49 to $50.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

BTIG analyst Thomas Shrader reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $10 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the price target from $25 to $10.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and maintains $45 price target.

Benzinga Newsdesk

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

Ascendiant Capital analyst Edward Woo maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and raises the price target from $48 to $49.

Benzinga Newsdesk

NRX Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

NRX Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

People Also Watch

People Also Watch

NRX Pharmaceuticals Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

NRX Pharmaceuticals Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROAscendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

PROBTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

PROHC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PROBTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

PROHC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PROAscendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49

People Also Watch

People Also Watch

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50

PRO
BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PRO
BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

PRO
HC Wainwright & Co. Reiterates Buy on NRX Pharmaceuticals, Maintains $45 Price Target

PRO
Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $49